G. Manson, C. Herbaux, and P. Brice, Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma, Blood, vol.131, issue.25, pp.2856-2859, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01812478

B. M. Haverkos, D. Abbott, and M. Hamadani, PD-1 blockade for relapsed lymphoma postallogeneic hematopoietic cell transplant: high response rate but frequent GVHD, Blood, vol.130, issue.2, pp.221-228, 2017.

C. Herbaux, J. Gauthier, and P. Brice, Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma, Blood, vol.129, issue.18, pp.2471-2478, 2017.

K. Fujita, N. Uchida, O. Kanai, M. Okamura, K. Nakatani et al., Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases, Cancer Chemother Pharmacol, vol.81, issue.6, pp.1105-1109, 2018.

M. Nomura, A. Otsuka, and T. Kondo, Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab, Cancer Chemother Pharmacol, vol.80, issue.5, pp.999-1004, 2017.

S. M. Ansell, A. P. Timmerman, and J. M. , Nivolumab re-treatment in patients with relapsed/refractory Hodgkin lymphoma. Presented at the 11 th International Symposium on Hodgkin Lymphoma, Abstract #0116, 2018.

R. Chen, P. L. Zinzani, and H. J. Lee, Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087, Blood, vol.134, issue.14, pp.114-1153, 2019.